Jyong Biotech Ltd(US:MENS) Globenewswire·2025-07-22 14:40Core Insights - Jyong Biotech Ltd. has completed its Nasdaq IPO and participated in the BIO 2025 International Convention, enhancing its visibility in the global biotechnology market [1][2][3] Company Overview - Jyong Biotech is a Taiwan-based biotechnology company focused on developing plant-derived drugs for urinary system diseases, targeting markets in the U.S., EU, and Asia [1][5] - The company has been operational since 2002 and has developed integrated capabilities across drug discovery, clinical trials, regulatory affairs, manufacturing, and commercialization [5] Product Focus - The flagship product, MCS-2, targets the benign prostatic hyperplasia (BPH) market, which is projected to grow from $4.1 billion in 2020 to $9.8 billion by 2026, driven by global aging and rising obesity rates [2] - MCS-2 aims to provide safe therapeutic solutions in a market traditionally dominated by synthetic drugs [3][4] Strategic Initiatives - The company plans to maximize MCS-2's market penetration through regional licensing partnerships and is exploring opportunities in emerging markets [4] - Jyong Biotech is executing a dual-track approach focusing on global licensing and sales network expansion for MCS-2 while continuing research and development in the urology sector [4] Leadership Perspective - Chairwoman Fu-Feng Kuo emphasized the company's commitment to meeting the urgent demand for safe medications in an aging society and establishing a new standard for plant-based drug innovation globally [5]